Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Targeted Anticancer Therapies Congress 2025

03 - 05 Mar 2025

Paris, France

ESMO-TAT-2025-1000x1000

Abstracts and ePosters: Open Access
Slides and Webcasts: Available to ESMO Members and registered delegates, subject to presenters' consent

The copyright protected educational resources from this event are for personal usage only and not to be shared with any third partiesESMO thanks the authors for their generosity.

The ESMO TAT Congress is dedicated to improving the conduct of early phase clinical trials in oncology by providing the latest scientific breakthroughs as well as workshops and educational reviews on pre-clinical and early clinical data.ESMO TAT 2025 is a multi-stakeholder forum in the early drug development arena, which bring together investigators from academia, translational scientists, methodological experts and opinion leaders from industry, investor and regulatory bodies to highlight new data, promote collaboration and tackle challenges for accelerating the bench-to-bedside pathway to the benefit of our patients

Click here to access the official Abstract book of the ESMO Targeted Anticancer Therapies, a supplement to ESMO Open.

Resources from ESMO Colloquia
Hide
Filter by:

There are 203 resources available

Q&A and discussion

Session: Artificial intelligence (AI) in drug development

Resources:

Webcast

Q&A and discussion

Session: Workshop in collaboration with ESMO YOC: Patient participatory research

Resources:

Webcast

Introduction

Presenter: Giovanni Abbadessa

Session: The corporate and investor mindset: What types of anti-cancer drugs and clinical research proposals will be prioritised in the near term?

Resources:

Slides

Webcast

The small company perspective

Presenter: Laura Soucek

Session: The corporate and investor mindset: What types of anti-cancer drugs and clinical research proposals will be prioritised in the near term?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.